Affiliation:
1. College of Pharmaceutical Science, Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, China
2. School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China
Abstract
Overexpression of human epidermal growth factor receptor (HER)-2 is found in a
variety of cancers, often portending poor clinical outcomes. Therefore, HER2 is an attractive
target for treatment. This review describes the research progress of HER2 targeted inhibitors
in recent years. Excellent reviews are available, so we focus on the development, mechanisms
of action, and structure-activity relationships of different types of inhibitors, including
monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates (ADCs). In
addition, the differences among them are compared.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献